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Lowering mutant Huntingtin is a consensus therapeutic strategy for Huntington’s disease. In this issue of
Neuron, Kordasiewicz et al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to
degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.Huntington’s disease (HD) is one of the
most common dominantly inherited
neurodegenerative disorders, character-
ized by a clinical triad of movement
disorder, cognitive deficits, and psychi-
atric symptoms. The average age of onset
for HD is around 40 years old. HD is relent-
lessly progressive and patients eventually
succumb to disease complications about
20 years after symptom onset. HD neuro-
pathology is characterized by selective
and massive degeneration of the striatal
neurons and to a lesser extent the deep-
layer cortical neurons; however, other
brain regions such as the thalamus,
hippocampus, and white matter (e.g.,
corpus callosum) are also affected in
patients. Currently, there is no effective
therapy to prevent the onset or slow the
progression of HD.
Because of its monogenetic etiology,
HD is a tractable model to study patho-
genesis and develop rational therapeu-
tics for a neurodegenerative disorder. HD
is caused by a CAG repeat expansion en-
coding an elongated polyglutamine
(polyQ) repeat near the N terminus of the
Huntingtin (Htt) protein. The precise
molecular functions of Htt remain incom-
pletely understood, but it is essential for
embryonic development and adult
neuronal survival, at least in mice (e.g.,
Dragatsis et al., 2000). Studies in a
plethora of model systems have yielded
numerous potential pathogenic pathways
and targets that could modify mutant Htt
(mHtt)-induced phenotypes (Ross and
Tabrizi, 2011). Several such pathways
appear to exert largedisease-suppressing
effects in animalmodels (Ross andTabrizi,
2011), but candidate therapies targeting
these pathways remain to be developed.964 Neuron 74, June 21, 2012 ª2012 ElsevieAlthough consensus molecular targets
that can counteract the toxic conse-
quences of mHtt are yet to emerge, an
unequivocal target for HD therapy is
mHtt itself. HD presents a prime opportu-
nity to test the hypothesis that lowering
levels of a toxic disease-causing protein
in proper cell types and disease stages
should have a large therapeutic effect.
The proof-of-concept experiment to
support such a notion came from a condi-
tional, tet-regulatable mouse model ex-
pressing mHtt exon1 fragment, in which
shutting down mHtt fragment expression
after disease onset leads to a reversal of
behavioral deficits, neurodegenerative
pathology, and mHtt aggregation (Yama-
moto et al., 2000). However, lowering Htt
as a therapeutic strategy is not without
potential risks. In mice, conditional dele-
tion of endogenous Htt in the forebrain
neurons results in progressive neurode-
generation (Dragatsis et al., 2000), sug-
gesting that a minimal level of Htt may
be necessary for the survival of certain
adult neurons.
While theoretically mHtt can be targeted
at the levels of DNA, RNA, or protein, the
most advanced Htt-lowering therapeutics
to date have been directed toward Htt
messenger RNA (mRNA). The first
successful strategy to reduce Htt mRNA
was through RNA interference (RNAi) by
the Davidson group (Harper et al., 2005),
inwhichstriatal injectionsofadeno-associ-
ated virus (AAV) expressing a short hairpin
RNA (shRNA) lead to a reduction of mHtt
and its aggregates and amelioration of
motor deficits in an mHtt fragment model.
Subsequent improvements of the strategy
resulted in AAV-mediated delivery of a less
toxic but equally efficacious artificial mi-r Inc.croRNA (miRNA) against mHtt (McBride
et al., 2008). A second RNAi strategy, by
direct striatal infusion of synthetic small
interfering RNA (siRNA) duplex, has also
shownefficacy inmitigatingmHtt fragment
toxicities in striatal neurons (DiFiglia et al.,
2007). These RNAi strategies lay a solid
foundation for Htt-lowering therapies for
HD. However, several lingering questions
remain to be addressed. First, can such
a therapy maintain its efficacy and safety
profiles in situations requiring chronic
administration, such as in the more slowly
progressive full-length mHtt mouse
models? Second, are there alternative
ways to deliver Htt-lowering therapy to
broader brain regions and cell types
beyond the striatum that may also
contribute to symptoms of HD?
A study in this issue of Neuron by Kor-
dasiewicz et al. (2012) provides strong
preclinical evidence to support the use
of antisense oligonucleotides (ASOs) as
an Htt-lowering therapeutic for HD.
ASOs are single-stranded DNA oligonu-
cleotides (usually 8–50 nucleotides) that
target cellular mRNA transcripts via
complementary base pairing. The result-
ing DNA/RNA duplex undergoes catalytic
degradation of the RNA component by
RNase H, an enzyme present in most
mammalian cells. Importantly, the single-
stranded ASO can be recycled to mediate
multiple rounds of selective mRNA degra-
dation (Figure 1A). The stability and
potency of ASOs are due to the phosphor-
othioate backbone and 20-O-methox-
yethyl (MOE) deoxynucleotide (DNA)
sugar modifications, with specificity
conferred by bioinformatic analysis and
cell-based screening to optimize target
engagement while minimizing off-target
Figure 1. Transient ASO-Mediated Htt Lowering Produces Sustained Therapeutic Effect in HD Mice
(A) A schematic to show ASOs with phosphorothioate (PS) and 20-O-methoxyethyl (MOE) modifications that can target Htt RNA to form RNA/DNA duplex and
activate RNase H-mediated degradation of Htt mRNA. (B) A schematic to illustrate the ‘‘Huntingtin Holiday’’ effect, a transient lowering of mHtt by ASOs in HD
mice results in sustained therapeutic benefit beyond the period of disease protein suppression.
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Previewstoxicity (Bennett and Swayze, 2010). A
strength for ASOs as candidate thera-
peutic agents is the safety profiles in
human studies so far, with one approved
drug in clinical use and another 35 in clin-
ical development (Bennett and Swayze,
2010). Indeed, one such clinical study is
a phase I clinical trial of ASO-mediated
lowering of mutant SOD1 in familial amyo-
trophic lateral sclerosis, based on the
original preclinical study by Cleveland
and colleagues (Smith et al., 2006).
To test ASO therapy in HD models,
Kordasiewicz et al. (2012) first estab-
lished drug-like properties for the Htt
ASOs. In the BACHD model that
expresses full-length human mHtt (Gray
et al., 2008), a 2 week infusion of two
separate ASOs into the right ventricle,
one selectively targeting human and the
other targeting both human and murine
Htt, is sufficient to induce dose-depen-
dent and selective reduction of Htt for
up to 12 weeks, with Htt levels returning
to baseline at 16 weeks. The stability
and high potency of chemically modified
ASOs probably contribute to the lengthy
period of Htt lowering after transient
ASO infusion. The second surprising
finding from the pharmacokinetics study
is the broad distribution of ASOs in
many brain regions (e.g., cortex, striatum,
thalamus, midbrain, and brainstem) from
intraventricular ASO delivery. Such broad
diminution of mHtt synthesis in multiplebrain regions may be advantageous in
treating HD, since the ubiquitously ex-
pressed mHtt is likely to affect multiple
brain regions to cause the core clinical
symptoms of HD.
A strong point of the current study is the
use of three distinct transgenic mouse
models of HD, three Htt-targeting ASOs,
and seven independent preclinical trials
to demonstrate the efficacy of ASOs in
abating disease phenotypes in vivo. In
R6/2, an mHtt-exon1 transgenic mouse
model that exhibits aggressive and lethal
disease course, 4 week infusion of ASOs
at a symptomatic stage leads to 60%
lowering of mHtt exon1, amelioration of
brain atrophy, and prolonged survival.
However, the nuclear inclusion formation
was not modified by ASO treatment, sug-
gesting only partial improvement of
disease pathology in this model.
The therapeutic efficacy of Htt ASOs
was more thoroughly investigated in two
full-length human mHtt genomic trans-
genic mouse models, YAC128 and
BACHD. In the YAC128 model, which
expresses human full-length mHtt with
128Q (Slow et al., 2003), 2 week ASO infu-
sion results in 80% mHtt lowering and
significant improvement of motor coordi-
nation on rotarod test. However, treat-
ment initiated at a later and more symp-
tomatic age (6 months) leads only to
a trend, but not statistically significant
improvement, suggesting that earlierNeuronASO treatment may confer better thera-
peutic effect, at least in this model.
The most in-depth preclinical assess-
ments the authors performed with ASOs
were conducted in BACHD mice, which
express full-length human mHtt with 97Q
under endogenous genomic regulation
(Gray et al., 2008). BACHD mice exhibit
progressive motor and psychiatric-like
behavioral deficits (e.g., anxiety), selec-
tive cortical and striatal atrophy, and
confer good statistical power to detect
disease modification (Gray et al., 2008).
With 2 week intraventricular infusion of
human-selective ASOs in BACHD mice
at 6 months of age, the treated mice
show significant improvement in motor
coordination and open-field exploration
and reduction in anxiety at 8–12 months
of age. To further evaluate the potential
lasting beneficial effects of transient
ASO therapy, Kordasiewicz et al. (2012)
performed a second BACHD trial to infuse
ASOs at 6 months and assayed these
mice up to 15months of age. Surprisingly,
even 9 months after ASO infusion and
5 months after mHtt level returns to base-
line, ASO-treated BACHD mice still show
sustained benefits in motor and anxiety
behaviors. The results from neuropa-
thology are somewhat mixed, with ASO-
treated BACHD mice showing fewer
mHtt aggregates, but no rescue of the
brain atrophy phenotype. The latter
finding raises some questions about74, June 21, 2012 ª2012 Elsevier Inc. 965
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Previewswhether earlier ASOdelivery or a repeated
treatment regimen may be necessary to
ameliorate neurodegeneration.
In this tour de force preclinical study,
Kordasiewicz et al. (2012) also addressed
the issue of the safety and efficacy of tar-
geting endogenous Htt. They showed that
the infusion of ASOs against both human
and murine Htt into BACHD mice,
achieving up to a 75% reduction of human
mHtt and murine wild-type Htt, did not
alter therapeutic benefits. Moreover, in
wild-type mice, reducing Htt by about
75% did not elicit any aberrant motor
phenotypes. A final crucial piece of
preclinical information was the intrathecal
infusion of ASOs into rhesus monkeys,
showing that Htt could be reduced in
some of the brain regions affected in HD
(e.g., cortex) but not others (e.g.,
caudate). Intrathecal infusion, a much
less invasive method compared to intra-
ventricular or intraparenchymal injection,
is already approved for ASO delivery in
the ongoing ALS trial. While the current
study did not provide any safety data on
the infusion of Htt ASOs in the nonhuman
primates, necessary for further clinical
development, the work of Kordasiewicz
et al. (2012) presents an important
preclinical demonstration of the repro-
ducible benefit of ASO-mediated Htt-
lowering therapy in multiple HD mouse
models.
The most surprising and important
finding from the current study is the sus-
tained benefit of transient mHtt lowering,
with multiple phenotypic improvements
well beyond the period of disease target
suppression. This phenomenon has
been referred to as a ‘‘Huntingtin Holiday’’
by Carl Johnson, the Scientific Director of
the Hereditary Disease Foundation
(Figure 1B). The precise mechanisms
underlying this remarkable effect remain
unknown and should be investigated.
This finding does suggest that in HD
mice, and likely in patients, critical
disease symptomsmay arise from revers-
ible neuronal dysfunction, and transient
relief of the primary insult may help the
affected neurons to better handle the re-
expressed mHtt. The Huntingtin Holiday966 Neuron 74, June 21, 2012 ª2012 Elsevieeffect also points to a potential clinical trial
design with periodic infusion of Htt-
lowering therapy.
With Htt-lowering therapies primed for
clinical studies in HD, several pressing
issues remain to be clarified. First and
foremost, we need to know when in the
disease course and where in the brain
such therapies should be delivered. The
current study supports the intuition that
early ASO delivery may confer more
benefit to modify the disease course.
The question of where in the brain Htt-
lowering therapy should be delivered is
not yet resolved, but current models
support that mHtt in multiple cell types
may contribute to the disease (Gu et al.,
2005). Delineating precise cell-type
contributions to HD phenotypes will be
crucial to select optimal Htt-lowering
agents and delivery strategies for clinical
trials. The second question is whether
both mutant and wild-type Htt alleles
should be targeted indiscriminately, or if
allele-specific silencing is a better choice.
The latter strategy may minimize potential
toxicity due to lowering of endogenous
Htt in human, which may not be predicted
from animal studies. To this end, the
welcome news is that only a few single-
nucleotide polymorphisms may be able
to distinguish the majority of HD patient
alleles from control alleles, and allelic-
specific silencing can be achieved with
siRNAs or ASOs (e.g., Pfister et al.,
2009; Carroll et al., 2011). The third ques-
tion is the urgent need to develop
biomarkers that can report on the central
lowering of mHtt and early reversal of
neuronal dysfunction. Finally, the most
difficult question, and one still worth
pondering, is how well successful preclin-
ical studies of Htt-lowering therapies will
translate into HD clinical trials. Species
differences aside, one should keep in
mind that HD mouse models only recapit-
ulate a subset of the complex clinical
phenotypes of the patients, and most
Htt-lowering therapies so far have shown
partial but not full disease reversal in
such models. Keeping such limitations in
mind, the consistent benefit of Htt-
lowering therapy across different thera-r Inc.peutic reagents and model platforms, as
evidenced from the current study, will
undoubtedly energize the field to further
pursue such innovative and rational thera-
pies for HD.REFERENCES
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